These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2847458)

  • 21. [Anticoagulating activity and lytic action of the heparin-antithrombin III and antithrombin III-heparin-thrombin complexes on non-stabilized fibrin].
    Kudriashov BA; Pastorova VE; Liapina LA
    Biokhimiia; 1981 Nov; 46(11):2024-9. PubMed ID: 7317530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of complexes of heparin with plasma proteins on the anticoagulant and fibrinolytic activity of blood].
    Kudriashov BA; Pastorova VE; Liapina LA
    Fiziol Zh SSSR Im I M Sechenova; 1986 Dec; 72(12):1653-8. PubMed ID: 3817209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ; Slappendel RJ; van den Brom WE
    Am J Vet Res; 1985 Jul; 46(7):1460-2. PubMed ID: 4026027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulants and their site of action.
    Haas-Weston CF
    Southwest Med; 1971 Jun; 52(6):119-26. PubMed ID: 5559910
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mechanisms of heparin resistance and their clinical significance].
    Barkagan ZS; Lychev VG; Bishevskiĭ KM; Tsyvkina LP; Glazunova GA
    Ter Arkh; 1982; 54(8):77-82. PubMed ID: 6753220
    [No Abstract]   [Full Text] [Related]  

  • 26. The use of an automated analyzer in the evaluation of antithrombin III and heparin.
    Scully MF
    Semin Thromb Hemost; 1983 Oct; 9(4):309-20. PubMed ID: 6658462
    [No Abstract]   [Full Text] [Related]  

  • 27. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis.
    Barrowcliffe TW
    Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromatography of heparin on sepharose-lysine: molecular size fractionation and its relevance to thrombin and antithrombin III binding.
    Hatton MW; Berry LR; Kaur H; Koj A; Regoeczi E
    Can J Biochem; 1979 Oct; 57(10):1183-90. PubMed ID: 120212
    [No Abstract]   [Full Text] [Related]  

  • 29. Glycosaminoglycans as naturally occurring combinatorial libraries: developing a mass spectrometry-based strategy for characterization of anti-thrombin interaction with low molecular weight heparin and heparin oligomers.
    Abzalimov RR; Dubin PL; Kaltashov IA
    Anal Chem; 2007 Aug; 79(16):6055-63. PubMed ID: 17658885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antithrombin III].
    Boyer-Neumann C; Wolf M; Larrieu MJ
    Ann Biol Clin (Paris); 1987; 45(2):175-80. PubMed ID: 3619143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III.
    Lijnen HR; van Hoef B; Collen D
    Thromb Haemost; 1983 Aug; 50(2):560-2. PubMed ID: 6415849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of crude heparin and commercial preparation of Polish production].
    Jarzebiński J; Tońska S; Remiszewska H
    Acta Pol Pharm; 1989; 46(2):179-82. PubMed ID: 2561044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Possible mechanism of the synergistic effect of heparin and dihydroergotamine.
    Kakkar VV; Welzel D; Murray WJ; Malone P; Jones D
    Am J Surg; 1985 Oct; 150(4A):33-8. PubMed ID: 4051120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surface modification with functionally active heparin.
    Riesenfeld J; Olsson P; Sanchez J; Mollnes TE
    Med Device Technol; 1995 Mar; 6(2):24-31. PubMed ID: 10155375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanism of inhibition of blood coagulation (author's transl)].
    Kurachi K
    Tanpakushitsu Kakusan Koso; 1980 Dec; 25(13):1031-40. PubMed ID: 7025099
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of antithrombin III on the binding of heparin and its low molecular weight fraction CY 216 with endothelium in vitro].
    Psuja P
    Acta Haematol Pol; 1988; 19(3-4):143-9. PubMed ID: 2855291
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.